Cargando…

Burden of Prescription Drug Costs in the United States

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2003
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437156/ https://www.ncbi.nlm.nih.gov/pubmed/14613372 http://dx.doi.org/10.18553/jmcp.2003.9.1.91

Ejemplares similares

Prescription Drug Expenditures, Financial Burden, and Health Plan Satisfaction Among Medicare Beneficiaries
por: Curtiss, Frederic R.
Publicado: (2003)

Effects of Physician Report Cards, Knowledge of Drug Prices, and Financial Incentives in Prescription Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Hypertension, Prescription Drug Copayments, and Drug Therapy Adherence
por: Curtiss, Frederic R.
Publicado: (2003)

Clinical, Service, and Cost Outcomes of Computerized Prescription Order Entry
por: Curtiss, Frederic R.
Publicado: (2005)

How Do Seniors Respond to 100% Cost-Sharing for Prescription Drugs? Quality of the Evidence Underlying Opinions About the Medicare Part D Coverage Gap
por: Fairman, Kathleen A., et al.
Publicado: (2011)

TMAC Savings of 90% for Heartburn Drugs in the United States
por: Curtiss, Frederic R.
Publicado: (2006)

Contradictory Actions on Off-Label Use of Prescription Drugs? The FDA and CMS Versus the U.S. Justice Department
por: Curtiss, Frederic R.
Publicado: (2009)

Prior Authorization to Manage Drug Utilization and Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Prescription-Equivalent Over-the-Counter Drugs for Allergy, Heartburn, and Cholesterol Reduction
por: Curtiss, Frederic R.
Publicado: (2005)

Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010
por: Fairman, Kathleen A., et al.
Publicado: (2010)

The Elephant in the Pharmacy: Patient Choice Is the Big Challenge That No One Talks About in Affordability of Prescription Drugs
por: Fairman, Kathleen A., et al.
Publicado: (2007)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Contractual Arrangements Between HMOs and Medical Groups to Manage Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Clinical, Service, and Cost Outcomes of Drug Coverage Edits and Quanitity Limits
por: Curtiss, Frederic R.
Publicado: (2003)

Pressure on Pharmacy Benefit Managers for Disclosure and Demonstration of Value - Rebates and Drug Benegit Cost Savings
por: Curtiss, Frederic R.
Publicado: (2003)

The high cost of prescription drugs: causes and solutions
por: Vincent Rajkumar, S.
Publicado: (2020)

United States, The Last Venue for Direct-to-Customer Advertising, Props Up the Erectile Dysfunction Market
por: Curtiss, Frederic R.
Publicado: (2005)

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

False-Positive Versus True-Positive Drug-Drug Interactions With Warfarin
por: Curtiss, Frederic R.
Publicado: (2006)

The United States Drug Enforcement Administration and Prescription Opioid Production Quotas: An End Game of Eradication?
por: Schatman, Michael E, et al.
Publicado: (2020)

Heartburn in Consumer-Directed Health Care and the Cost Outcomes of Therapeutic Maximum Allowable Cost
por: Curtiss, Frederic R.
Publicado: (2006)

COPD - Whose Burden, How Large, and What to Do About It?
por: Curtiss, Frederic R.
Publicado: (2005)

Preventing Medication Errors and Adverse Drug Events
por: Curtiss, Frederic R.
Publicado: (2003)

COX-2 Inhibitors: Little or No GI Protection, Increased Risk of Cardiovascular Events, High Cost, and Other Class-less Effects
por: Curtiss, Frederic R.
Publicado: (2005)

HIPAA Effects on Health Research and PBM Functions in Drug Utilization Review
por: Curtiss, Frederic R.
Publicado: (2003)

VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?
por: Fairman, Kathleen A., et al.
Publicado: (2012)

More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
por: Curtiss, Frederic R.
Publicado: (2006)

Antihypertensive Drug Effects on Renal Function and Myocardial Infarction and Implications of the ALLHAT Study Results
por: Curtiss, Frederic R.
Publicado: (2003)

Economic burden of pediatric prescription opioid poisonings in the United States
por: Patel, Anisha M, et al.
Publicado: (2021)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Pharmacoeconomics - Determiniation of the Cost-Effectiveness of Helicobacter Pylori Eradication
por: Curtiss, Frederic R.
Publicado: (2003)

The Future of Prescription Drug Cost-Sharing: Real Progress or Dropped Opportunity?
por: Fairman, Kathleen A.
Publicado: (2008)

Omalizumab and Other New Drug Therapies Occupy a Small Space in Asthma Disease Management
por: Curtiss, Frederic R.
Publicado: (2009)

Protecting Patients from Adverse Drug Events: Propoxyphene, PIMs, and Drugs to Avoid in Older Adults
por: Curtiss, Frederic R., et al.
Publicado: (2011)

Which Triptan? - Opportunity for Same or Better Outcomes at Lower Cost
por: Curtiss, Frederic R.
Publicado: (2004)

David and Goliath - Employer Takes on Health Care Cost Management
por: Curtiss, Frederic R.
Publicado: (2004)

Reducing the Risk of Fractures - The Options Narrow for Cost-Effective Therapeutic Alternatives
por: Curtiss, Frederic R.
Publicado: (2004)

Diabetes Drug Therapy -- First Do No Harm
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Does Member Cost Sharing Pose a Threat to Desirable Patient Outcomes?
por: Curtiss, Frederic R.
Publicado: (2004)

Finding the Truth About Health Care Cost Drivers - Price Versus Utilization Factors
por: Curtiss, Frederic R.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_aprc9cpd01pe3lmr07udnr92tk